The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 12, 2021

Filed:

Sep. 05, 2019
Applicant:

Ngm Biopharmaceuticals, Inc., South San Francisco, CA (US);

Inventors:

Alexander Mark Depaoli, Santa Barbara, CA (US);

Jian Luo, Albany, CA (US);

Hui Tian, Foster City, CA (US);

Assignee:

NGM BIOPHARMACEUTICALS, INC., South San Francisco, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/18 (2006.01); G01N 33/92 (2006.01); G01N 33/68 (2006.01); A61P 1/00 (2006.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1825 (2013.01); A61P 1/00 (2018.01); G01N 33/5088 (2013.01); G01N 33/6848 (2013.01); G01N 33/92 (2013.01); G01N 2405/00 (2013.01); G01N 2800/08 (2013.01); G01N 2800/52 (2013.01);
Abstract

Provided herein are methods of using 7α-hydroxy-4-cholesten-3-one (C4) in predicting the clinical sensitivity to treatment of bile acid-related and associated disorders with treatment peptides, such as variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics).


Find Patent Forward Citations

Loading…